Pyxis Oncology Inc (NASDAQ:PYXS) has a beta value of 1.05 and has seen 2.34 million shares traded in the last trading session. The company, currently valued at $101.68M, closed the last trade at $1.89 per share which meant it lost -$0.01 on the day or -0.53% during that session. The PYXS stock price is -262.43% off its 52-week high price of $6.85 and 28.57% above the 52-week low of $1.35. If we look at the company’s 10-day average daily trading volume, we find that it stood at 3.09 million shares traded. The 3-month trading volume is 900.82K shares.
The consensus among analysts is that Pyxis Oncology Inc (PYXS) is Buy stock at the moment, with a recommendation rating of 1.25. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 2 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.32.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Pyxis Oncology Inc (NASDAQ:PYXS) trade information
Sporting -0.53% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the PYXS stock price touched $1.89 or saw a rise of 56.15%. Year-to-date, Pyxis Oncology Inc shares have moved 5.00%, while the 5-day performance has seen it change -53.79%. Over the past 30 days, the shares of Pyxis Oncology Inc (NASDAQ:PYXS) have changed -48.36%. Short interest in the company has seen 5.86 million shares shorted with days to cover at 10.78.
Wall Street analysts have a consensus price target for the stock at $10, which means that the shares’ value could jump 81.1% from current levels. The projected low price target is $7.0 while the price target rests at a high of $10.0. In that case, then, we find that the current price level is -429.1% off the targeted high while a plunge would see the stock gain -270.37% from current levels.
Pyxis Oncology Inc (PYXS) estimates and forecasts
Figures show that Pyxis Oncology Inc shares have outperformed across the wider relevant industry. The company’s shares have lost -49.47% over the past 6 months, with this year growth rate of 44.32%, compared to 16.70% for the industry. Revenue growth from the last financial year stood is estimated to be 0.00%.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -118.72% over the past 5 years. Earnings growth for 2024 is a modest 41.24% while over the next 5 years, the company’s earnings are expected to increase by 34.60%.
PYXS Dividends
Pyxis Oncology Inc is expected to release its next earnings report in December this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Pyxis Oncology Inc (NASDAQ:PYXS)’s Major holders
Insiders own 24.54% of the company shares, while shares held by institutions stand at 54.52% with a share float percentage of 72.25%. Investors are also buoyed by the number of investors in a company, with Pyxis Oncology Inc having a total of 125.0 institutions that hold shares in the company. The top two institutional holders are DEEP TRACK CAPITAL, LP with over 4.18 million shares worth more than $13.85 million. As of 2024-06-30, DEEP TRACK CAPITAL, LP held 8.1578% of shares outstanding.
The other major institutional holder is LAURION CAPITAL MANAGEMENT LP, with the holding of over 3.86 million shares as of 2024-06-30. The firm’s total holdings are worth over $12.78 million and represent 7.5282% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are iShares Russell 2000 ETF and Vanguard Total Stock Market Index Fund . As of Sep 30, 2024 , the former fund manager holds about 2.09% shares in the company for having 1.24 shares of worth $2.35 million while later fund manager owns 905.32 shares of worth $1.71 million as of Jun 30, 2024 , which makes it owner of about 1.52% of company’s outstanding stock.
